139 results
424B5
AGIO
Agios Pharmaceuticals Inc
9 Dec 14
Prospectus supplement for primary offering
12:00am
of common stock
S-14
Dividend policy
S-14
Capitalization
S-15
Dilution
S-16
Material U.S. tax considerations for non-U.S. holders of common stock
S-17 … into account further dilution to new investors that could occur upon the issuance of notes in the concurrent notes offering.
S-16
Material U.S. tax
10-Q
2013 Q2
AGIO
Agios Pharmaceuticals Inc
5 Sep 13
Quarterly report
12:00am
and negative evidence bearing upon the realizability of its
deferred tax assets, which are comprised principally of timing
differences related … to the recognition of revenue under the Celgene
Agreement for book versus tax purposes. During the year ended
December 31, 2011, management determined
8-K
EX-99.1
w2mx0au2ufo4omisl
29 Jan 21
Index to Consolidated Financial Statements
4:08pm
10-Q
p033k2ye
5 Sep 13
Quarterly report
12:00am
424B5
74v5x 95x
6 Nov 19
Prospectus supplement for primary offering
4:07pm
424B5
4z99t5dp j8wy
11 Dec 14
Prospectus supplement for primary offering
12:00am
10-Q
3inqfnlk92q dvxtw8
5 Sep 13
Quarterly report
12:00am
S-8
EX-99.2
w9c8173dtyckp
26 Sep 22
Registration of securities for employees
5:19pm
10-Q
ketpy6iq znvh3z5ycl
5 Sep 13
Quarterly report
12:00am
8-K
lay1jb
8 Sep 20
Agios Appoints Jonathan Biller as Chief Financial Officer, Head of Legal and Corporate Affairs
4:09pm
424B5
c6u 9jy9zp
8 Nov 19
Prospectus supplement for primary offering
5:03pm
S-1
EX-10.1
1jyhl8en0d5i
10 Jun 13
IPO registration
12:00am